Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Amphetamines Stories

2011-06-01 12:57:53

Animal study suggests having a lifelong mate leads to greater resistance to drug Long-term relationships make the commonly abused drug amphetamine less appealing, according to a new animal study in the June 1 issue of The Journal of Neuroscience. The findings suggest that social bonds formed during adulthood lead to changes in the brain that may protect against drug abuse. Prairie voles are rodents that form lifelong bonds with mating partners. In the new study, researchers directed by Zuoxin...

2011-05-25 06:00:00

DUBLIN, May 25, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that its subsidiary Shire LLC has received Paragraph IV Notice Letters from Amneal Pharmaceuticals, LLC. ("Amneal") and Watson Laboratories, Inc. ("Watson"), advising of the filing of Abbreviated New Drug Applications ("ANDA") by each company for generic version of all strengths of lisdexamfetamine dimesylate capsules, VYVANSE. These are the second...

2011-05-23 00:00:27

Top selling Sinupret® and Bronchipret® now available only through Bioforce USA Ghent, NY (PRWEB) May 22, 2011 Bioforce USA is pleased to announce that it has acquired the distribution rights for Bionorica products in the US, effective immediately. This includes the top selling products Sinupret® and Bronchipret®. Bionorica is one of the most highly regarded herbal products manufacturers in the world, having been recognized by the American Botanical Council (ABC) for its...

2011-05-19 09:23:00

DUBLIN, May 19, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that its subsidiary Shire LLC has received a Paragraph IV Notice Letter from Sandoz Inc. ("Sandoz") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of all strengths of lisdexamfetamine dimesylate capsules, VYVANSE. This is the first Paragraph IV Notice Letter directed to VYVANSE received by the company....

2011-05-13 19:30:00

Stop Sale Technology Will Allow Consumers Access To Cold & Allergy Medicines, While Blocking Criminals WASHINGTON, May 13, 2011 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) today released the following statement in response to Indiana Governor Mitch Daniels signing into law a bill that requires the state to track all purchases of products containing pseudoephedrine (PSE) in real time allowing retailers and pharmacists to block sales to any...

2011-05-11 19:32:02

Scientists are reporting development of three promising formulations that could be used in a vaccine to treat methamphetamine addiction "” one of the most serious drug abuse problems in the U.S. The report appears in the Journal of the American Chemical Society. In the paper, Kim Janda and colleagues note that methamphetamine use and addiction cost the U.S. more than $23 billion annually due to medical and law enforcement expenses, as well as lost productivity. The drug, also called...

2011-05-09 21:17:00

WASHINGTON, May 9, 2011 /PRNewswire-USNewswire/ -- The following is a statement by Scott M. Melville, president and CEO of the Consumer Healthcare Products Association (CHPA), in response to the Missouri House passing legislation making over-the-counter cold and allergy medicines containing pseudoephedrine (PSE) available only by obtaining a doctor's prescription: "Today's vote in the Missouri House of Representatives in support for legislation requiring a doctor's prescription to access...

2011-04-28 04:00:00

PHILADELPHIA, April 28, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia. This study met its pre-defined primary end points. Vyvanse is a prescription medicine currently approved in the US, Canada,...

2011-04-25 07:33:00

NORTH LIBERTY, Iowa, April 25, 2011 /PRNewswire/ -- KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder (ADHD), will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106. KP106 is a new chemical entity (NCE) comprised of d-amphetamine, and was identified utilizing KemPharm's proprietary...

2011-04-25 07:33:00

WARREN, N.J., April 25, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease. Under terms of the agreement, the...